{
    "clinical_study": {
        "@rank": "89169", 
        "arm_group": [
            {
                "arm_group_label": "HMS5552 dose 1", 
                "arm_group_type": "Experimental", 
                "description": "HMS5552 25~400mg. Oral administration, twice per day."
            }, 
            {
                "arm_group_label": "HMS5552 dose 2", 
                "arm_group_type": "Experimental", 
                "description": "HMS5552 25~400mg. Oral administration, twice per day."
            }, 
            {
                "arm_group_label": "HMS5552 dose 3", 
                "arm_group_type": "Experimental", 
                "description": "HMS5552 25~400mg. Oral administration, twice per day."
            }, 
            {
                "arm_group_label": "HMS5552 dose 4", 
                "arm_group_type": "Experimental", 
                "description": "HMS5552 25~400mg. Oral administration, once per day."
            }, 
            {
                "arm_group_label": "HMS5552 dose 5", 
                "arm_group_type": "Experimental", 
                "description": "HMS5552 25~400mg. Oral administration, twice per day."
            }, 
            {
                "arm_group_label": "HMS5552 dose 6", 
                "arm_group_type": "Experimental", 
                "description": "HMS5552 25~400mg. Oral administration, twice per day."
            }, 
            {
                "arm_group_label": "HMS5552 dose 7", 
                "arm_group_type": "Experimental", 
                "description": "HMS5552 25~400mg. Oral administration, twice per day."
            }, 
            {
                "arm_group_label": "HMS5552", 
                "arm_group_type": "Experimental", 
                "description": "HMS5552 25~400mg. Oral administration, once per day."
            }
        ], 
        "brief_summary": {
            "textblock": "The objectives of this study is to determine the safety, tolerability, pharmacokinetics and\n      pharmacodynamics of HMS5552 following multiple ascending doses in patients with type 2\n      diabetes mellitus."
        }, 
        "brief_title": "Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HMS5552 in Patients With Type 2 Diabetes", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Type 2 Diabetes Mellitus", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "detailed_description": {
            "textblock": "This will be a randomized, double-blind and placebo-controlled study with multiple oral\n      doses of HMS5552 given to patients with type 2 diabetes mellitus who never accepted\n      anti-diabetic drug for treatment before.\n\n      The primary objective is to characterize the safety and tolerability of HMS5552 following\n      multiple ascending doses in patients with type 2 diabetes mellitus after BID dosing for 8\n      days.\n\n      The secondary objectives include:\n\n        1. To determine the single dose and steady state pharmacokinetics of HMS5552 in patients\n           with type 2 diabetes\n\n        2. To evaluate the single dose and steady state pharmacodynamics of HMS5552 in patients\n           with type 2 diabetes\n\n        3. To further explore food-effect on HMS5552 pharmacokinetics and pharmacodynamics\n\n      A maximum total of 80 patients (10 in each dose group and assuming a maximum of 8 dose\n      levels). There will be 8 active and 2 placebo patients in each dose group. The safety,\n      tolerability, pharmacokinetics and pharmacodynamics data after each dose cohort will be\n      reviewed in blinded fashion before escalation to the next dose cohort."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male and female subjects with type 2 diabetes who never accepted anti-diabetic drug\n             for treatment before\n\n          -  Age: 18 to 65 years\n\n          -  BMI: 20 to 29 kg/m2\n\n          -  Mentally, physically and legally eligible to give informed consent.\n\n          -  Willingness to adhere to the protocol requirement.\n\n        Exclusion Criteria:\n\n          -  Subjects with type 1 diabetes\n\n          -  Episodes of hypoglycemia\n\n          -  Unstable cardiovascular diseases\n\n          -  Hepatic diseases\n\n          -  Kidney disease\n\n          -  Mental or central nervous system diseases\n\n          -  Clinical abnormal findings in ECG, labs and physical exams"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "80", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 2, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02077452", 
            "org_study_id": "HMM0102"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "HMS5552 dose 1", 
                    "HMS5552 dose 2", 
                    "HMS5552 dose 3", 
                    "HMS5552 dose 4", 
                    "HMS5552 dose 5", 
                    "HMS5552 dose 6", 
                    "HMS5552 dose 7", 
                    "HMS5552"
                ], 
                "intervention_name": "HMS5552", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "HMS5552 dose 1", 
                    "HMS5552 dose 2", 
                    "HMS5552 dose 3", 
                    "HMS5552 dose 4", 
                    "HMS5552 dose 5", 
                    "HMS5552 dose 6", 
                    "HMS5552 dose 7", 
                    "HMS5552"
                ], 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Glucokinase activator", 
            "Phase I", 
            "Type 2 diabetes mellitus"
        ], 
        "lastchanged_date": "March 3, 2014", 
        "number_of_arms": "8", 
        "official_title": "A Randomized, Double-blinded, Placebo-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Ascending Doses of HMS5552 in Adult Patients With Type 2 Diabetes Mellitus", 
        "overall_contact": {
            "email": "yzhang@huamedicine.com", 
            "last_name": "YI ZHANG, MD", 
            "phone": "+86-021-20283269"
        }, 
        "overall_official": {
            "affiliation": "Nanjing Drum Tower Hospital", 
            "last_name": "Dalong ZHU, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Safety and tolerability of HMS5552 will be assessed by adverse event monitoring, physical examinations, 12 lead ECGs, vital sign, and safety laboratory measurements.", 
            "safety_issue": "Yes", 
            "time_frame": "up to 15 days after study drug administration"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02077452"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Single dose (Day 1) plasma and urine pharmacokinetic parameters (postprandial)\nSingle dose (Day 3) plasma and urine pharmacokinetic parameters (fasting)\nSteady state (Day 7) plasma and urine pharmacokinetic parameters (postprandial)\nSteady state (Day 8) plasma and urine pharmacokinetic parameters (fasting)", 
                "measure": "The single dose and steady state pharmacokinetics (with food and fasting) of HMS5552 will be described by estimating parameters of AUCinf, AUC0-t, Cmax, Tmax, Ae, T1/2, CL/f, CLr/f, accumulation index and fluctuation index.", 
                "safety_issue": "No", 
                "time_frame": "up to day 8 post-dose"
            }, 
            {
                "measure": "The single dose and steady state (fasting and postprandial) pharmacodynamic variables will include maximum absolute and percent change in plasma glucose level, AUC0-4, AUC0-16, AUC16-24, AUC0-24 hr of plasma glucose.", 
                "safety_issue": "No", 
                "time_frame": "up to 4 hour post-dose and up to 24 hour post-dose"
            }, 
            {
                "measure": "Insulin, C-peptide, glucagon and glucagon-like peptide 1 up to 6hr post-dose following single dose and steady state (fasting and postprandial)", 
                "safety_issue": "No", 
                "time_frame": "up to 6 hour post-dose"
            }
        ], 
        "source": "Hua Medicine Limited", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hua Medicine Limited", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}